Contact allergy in patients with rosacea: a clinic-based, prospective epidemiological study.
BACKGROUND
Rosacea is a relatively common inflammatory skin disease of unknown prevalence. The proportion of contact allergy complicating rosacea and its therapy, respectively, is largely unknown.


OBJECTIVE
To estimate the prevalence of specific contact allergy in rosacea patients and to compare this with the prevalence observed in the general population and in general patch test patients.


METHODS
In this prospective monocentre study, 78 patients with rosacea were investigated for contact sensitizations via patch testing the standard series, constituents of topical formulations, preservatives, fragrances, topically applied drugs and, if available, patient's own products.


RESULTS
Positive reactions occurred to nickel (II) sulphate (12 of 78, 15.4%), fragrance mix I (4 of 77, 5.2%), balsam of Peru (8 of 77, 10.4%; significantly elevated prevalence compared to that observed in the population-based KORA study), potassium dichromate (4 of 78, 5.1%) and Lyral (3 of 78, 3.8%). Regarding topical antibiotics, only 1 of 78 (1.3%) patients was positive to neomycin sulphate, and none to metronidazole; however, 6 of 75 (8%) patients were positive to gentamicin sulphate, and 4 of 76 (5.3%) patients were positive to framycetin sulphate. No allergic but irritant patch test reactions, instead, were provoked by various patients' own products as well as by the irritant sodium lauryl sulphate (SLS) even in low concentrations.


CONCLUSIONS
Despite the limited power of the study, a strikingly high prevalence of contact allergy to gentamicin sulphate was observed, which is probably due to antibiotic treatment of rosacea-associated eye symptoms. The reactions to the irritant SLS probably mirror the extreme skin sensitivity in rosacea.
Jappe
U
U
Department of Dermatology, University of Heidelberg, Medical University Schleswig-Holstein, Campus Luebeck, Germany. japut@pei.de
Schäfer
T
T
Schnuch
A
A
Uter
W
W
D000287:Administration, Topical; D003877:Dermatitis, Contact / Q000150:complications*; D006801:Humans; D010328:Patch Tests; D011446:Prospective Studies; D012393:Rosacea / Q000150:complications* / Q000188:drug therapy